As filed with the United States Securities and Exchange Commission on June 20, 2024 Registration No. 333-279336 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TENON MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) Delaware 3841 45-5574718 (I.R.S. Employer Identif ...

Financial Data and Key Metrics Changes - Revenue for Q1 2024 was $719,000, a 66% increase compared to $433,000 in Q1 2023, primarily driven by a 42% rise in surgical procedures using the Catamaran system [17][7][20] - Gross profit in Q1 2024 was $470,000, representing a gross margin of 65%, compared to a gross loss of $47,000 in the same period last year [18][20] - Operating losses decreased to $3.5 million in Q1 2024 from $4.9 million in Q1 2023, with net loss also improving to $3.6 million from $4.8 million [19][20] Business Line Data and Key Metrics Changes - The Catamaran system saw a 42% increase in surgical procedures during Q1 2024, contributing to the overall revenue growth [7][17] - The company reported its fourth consecutive quarter of positive gross profit, maintaining a steady gross margin of 65% [7][18] Market Data and Key Metrics Changes - Coverage was achieved in two of five geographic regions, with new personnel added to enhance market penetration [6][5] - The company is focusing on a go-to-market strategy targeting SI-focused physicians and network partners [6][5] Company Strategy and Development Direction - The company is prioritizing the scale of its commercialization strategy for the Catamaran system, aiming to broaden its strategic marketing and promotion efforts [22][13] - The addition of Kristine Jacques to the Board of Directors is expected to provide valuable insights into go-to-market strategies in the medical device field [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing momentum in the market, supported by year-over-year increases in Catamaran procedures and positive interim clinical results [23][24] - The company is committed to delivering technologies that improve patient outcomes while pursuing long-term value for shareholders [24] Other Important Information - The company generated $2.6 million from a preferred stock raise and retired $1.25 million in secured debt during Q1 2024, strengthening its balance sheet [15][20] - The ongoing post-market clinical study is nearing completion of enrollment, with interim analysis expected in fall 2024 [10][9] Q&A Session Summary Question: What is the mix between interventional pain physicians and spine surgeons in the workshops? - The company reported a 50-50 mix between orthopedic and neuro spine surgeons and interventional pain surgeons in their workshops [26] Question: How many patients were in the first group of data released from the post-market study? - The first group included six patients who reached the 12-month milestone, with future data releases expected to show increasing numbers [28][31] Question: What is the maximum number of patients for the study and when will physicians feel comfortable using the data? - The study is set for a maximum of 50 patients, with physicians likely to be influenced by the interim analysis at the 12-month mark [32][33] Question: How many active sites are involved in the study? - There are currently eight active sites, with enrollment nearing completion [38] Question: How does the company anticipate the rollout of physician training? - The company expects an increase in training volume as compelling clinical data becomes available, leading to more inquiries from physicians [41] Question: What is the expected gross margin at normal volume? - The company anticipates maintaining a gross margin of around 65% initially, with potential to reach mid-70s as volumes increase [46][48]

Revenue and Profitability - Revenue for the three months ended March 31, 2024, was $719,000, a 66% increase from $433,000 in the same period of 2023, primarily due to a 42% increase in the number of surgical procedures using The Catamaran System[93][94] - Gross profit for the same period improved to $470,000, compared to a loss of $47,000 in 2023, resulting in a gross margin of 65% compared to (11)% in the prior year[93][94] - The net loss for the three months ended March 31, 2024, was $3,576,000, compared to a net loss of $4,830,000 in the same period of 2023[93] Operating Expenses - Total operating expenses decreased by 18% to $3,976,000 in Q1 2024 from $4,839,000 in Q1 2023, driven by reductions in research and development, sales and marketing, and general and administrative expenses[96] - Research and development expenses decreased by 20% to $669,000 in Q1 2024 from $834,000 in Q1 2023, primarily due to lower professional fees and payroll expenses[96] - Sales and marketing expenses fell by 32% to $1,381,000 in Q1 2024 from $2,026,000 in Q1 2023, attributed to reduced transition fees and payroll expenses[97] - General and administrative expenses slightly decreased by 3% to $1,926,000 in Q1 2024 from $1,979,000 in Q1 2023, with increased insurance costs partially offsetting reductions in professional service fees[98] Cash Flow and Financing - As of March 31, 2024, the company had cash and cash equivalents of $4.4 million and no outstanding debt[100] - The company reported a net cash used in operating activities of $(2,338) thousand for the three months ended March 31, 2024, a 35% improvement from $(3,576) thousand in the same period of 2023[104] - Cash provided by financing activities for the three months ended March 31, 2024 was $4,371 thousand, a significant increase from $(42) thousand in the same period of 2023, representing a 10,507% change[104] - The company plans to raise additional capital through public or private equity offerings, debt financings, and collaborations, which may dilute existing stockholders' ownership[103] - The company entered into a Series A Purchase Agreement on February 20, 2024, raising an aggregate offering price of $2,605,000 through the sale of 172,239 shares of Series A Preferred Stock and warrants[102] - The company experienced a net increase in cash and cash equivalents of $1,960 thousand for the three months ended March 31, 2024, an 87% increase from $1,050 thousand in the same period of 2023[104] - The company has not achieved positive cash flow from operations to date and anticipates that existing cash will not be sufficient to fund operating expenses for the next 12 months[101] - The company reported a decrease in cash provided by investing activities to $(119) thousand for the three months ended March 31, 2024, compared to $4,669 thousand in the same period of 2023, a 103% decline[104] Company Overview and Future Outlook - The company launched The Catamaran System nationally in October 2022 and is building a sales and marketing infrastructure to address the market opportunity[79] - The company has an accumulated deficit of approximately $58.6 million as of March 31, 2024, since its inception in 2012[81] - As of March 31, 2024, the company had an accumulated deficit of $58.6 million and expects to incur additional losses in the future[101] - Management believes there is substantial doubt about the company's ability to continue as a going concern for the next twelve months from the issuance of the consolidated financial statements[103] - As of March 31, 2024, the company had a total of 256,968 shares of Series A Preferred Stock outstanding[102]

As filed with the United States Securities and Exchange Commission on May 10, 2024 Registration No. 333-[*] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TENON MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 3841 45-5574718 (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 104 Cooper ...

Part I [Business](index=7&type=section&id=Item%201%20Business) Tenon Medical, Inc. launched its FDA-cleared Catamaran™ SI Joint Fusion System in October 2022, targeting a potential **$2.0 billion** U.S. market for SI joint disorders - The company developed the Catamaran™ SI Joint Fusion System, receiving FDA clearance in **2018** for treating SI Joint disorders[24](index=24&type=chunk) - Tenon estimates the potential annual U.S. market for SI-Joint surgical intervention at approximately **$2.0 billion**, with current market penetration at only **5-7%**[42](index=42&type=chunk)[43](index=43&type=chunk) - The company initiated its national commercial launch in **October 2022**, marketing its product primarily through independent distributors and sales representatives[38](index=38&type=chunk)[67](index=67&type=chunk) - As of March 29, 2024, Tenon owns **4 issued U.S. utility patents** and **16 pending U.S. utility patent applications**, with U.S. patents expected to expire around **2031**[78](index=78&type=chunk)[80](index=80&type=chunk) - The company relies on **five contract manufacturers** for all instruments, implants, and sterilization cases, without long-term manufacturing agreements[108](index=108&type=chunk)[109](index=109&type=chunk) [Risk Factors](index=23&type=section&id=Item%201A%20Risk%20Factors) The company faces significant risks including recurring losses, going concern doubts, single product dependence, intense competition, and internal control weaknesses - The company has a history of recurring losses and negative cash flows, with its auditor expressing substantial doubt about its ability to continue as a going concern[120](index=120&type=chunk) - Tenon is solely dependent on the market adoption of its **single product**, the Catamaran System, where failure to increase sales would materially harm operations[144](index=144&type=chunk) - The company is dependent on a limited number of **single-source contract manufacturers**, where the loss of any could materially affect the business[154](index=154&type=chunk) - The company received a Nasdaq notice on **January 4, 2024**, for non-compliance with board and committee independence, potentially leading to delisting[251](index=251&type=chunk) - Management identified a **material weakness** in internal controls over financial reporting due to a lack of segregation of duties, stemming from limited size and resources[256](index=256&type=chunk) [Unresolved Staff Comments](index=53&type=section&id=Item%201B%20Unresolved%20Staff%20Comments) The company reports no unresolved staff comments - None [Cybersecurity](index=53&type=section&id=Item%201C%20Cybersecurity) The company maintains a cyber-risk management program overseen by the Board of Directors, and as of the report date, has not experienced any material cybersecurity attacks - The Board of Directors oversees the company's cyber-risk management program[274](index=274&type=chunk) - As of the report date, the company has not experienced any significant cybersecurity attacks that materially affected its business or financial condition[275](index=275&type=chunk) [Properties](index=53&type=section&id=Item%202%20Properties) The company leases its principal executive offices in Los Gatos, California, and owns no real estate - The company's principal executive offices are leased and located in Los Gatos, California[276](index=276&type=chunk) [Legal Proceedings](index=53&type=section&id=Item%203%20Legal%20Proceedings) The company reports no legal proceedings - None [Mine Safety Disclosures](index=53&type=section&id=Item%204%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable Part II [Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities](index=54&type=section&id=Item%205%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%2C%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock trades on Nasdaq under "TNON", with **3.7 million** shares outstanding as of March 2024, and it has never paid cash dividends - As of **March 29, 2024**, the company had **3,726,974 shares** of common stock outstanding[281](index=281&type=chunk) - The company has never declared or paid a cash dividend and does not expect to in the foreseeable future[282](index=282&type=chunk) - On **November 21, 2023**, the company issued **$1,250,000** in secured notes and warrants to purchase **45,000 shares** of common stock at **$1.94 per share** in a private placement[288](index=288&type=chunk)[290](index=290&type=chunk) | Plan Category | Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) | Weighted average exercise price of outstanding options, warrants and rights (b) | Number of securities remaining available for future issuance under equity compensation plans (c) | | :--- | :--- | :--- | :--- | | Equity compensation plans approved by security holders | 179,005 | $42.54 | 37,486 | | Equity compensation plans not approved by security holders | — | $ — | — | | Total | 179,005 | $42.54 | 37,486 | [Reserved](index=56&type=section&id=Item%206%20%5BReserved%5D) This item is reserved [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=57&type=section&id=Item%207%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) For 2023, revenue increased to **$2.9 million** from **$0.7 million** in 2022, with a net loss of **$15.6 million**, raising substantial doubt about its going concern ability | Consolidated Statements of Operations Data in Dollars (in thousands) | 2023 | 2022 | | :--- | :--- | :--- | | Revenue | $ 2,928 | $ 691 | | Gross profit (loss) | 1,241 | (641) | | Loss from operations | (15,727) | (18,725) | | Net loss | $ (15,581) | $ (18,917) | - The **312% increase** in 2023 revenue was primarily due to a rise in surgical procedures using the Catamaran System[345](index=345&type=chunk) - Sales and marketing expenses decreased by **13%** in 2023, primarily due to a **$3.6 million** payment in 2022 for a sales agreement termination, partially offset by increased payroll and commissions in 2023[347](index=347&type=chunk)[348](index=348&type=chunk) - The company had an accumulated deficit of **$55.1 million** as of December 31, 2023, with management stating existing cash is insufficient for the next 12 months, raising substantial doubt about its going concern ability[354](index=354&type=chunk) - In **February 2024**, the company raised **$2.6 million** through a private placement of Series A Preferred Stock and warrants[355](index=355&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=65&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) As a smaller reporting company, Tenon Medical is not required to provide this information - The Company is a smaller reporting company and is not required to provide the information under this item[365](index=365&type=chunk) [Financial Statements and Supplementary Data](index=66&type=section&id=Item%208%20Financial%20Statements%20and%20Supplementary%20Data) The consolidated financial statements for 2023 and 2022 include an auditor's "going concern" paragraph, showing total assets of **$6.3 million** and a net loss of **$15.6 million** for 2023 - The independent auditor's report for 2023 expresses substantial doubt about the Company's ability to continue as a going concern due to recurring losses, negative cash flows, and limited capital[372](index=372&type=chunk) | (In thousands) | December 31, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Total current assets | $ 3,889 | $ 9,347 | | TOTAL ASSETS | $ 6,345 | $ 11,089 | | **Liabilities and Stockholders' Equity** | | | | Total current liabilities | $ 3,140 | $ 2,530 | | Total liabilities | $ 5,567 | $ 4,837 | | Total stockholders' equity | $ 778 | $ 6,252 | | TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 6,345 | $ 11,089 | | (In thousands, except per share data) | Years Ended December 31, | | | :--- | :--- | :--- | | | 2023 | 2022 | | Revenue | $ 2,928 | $ 691 | | Net Loss | $ (15,581) | $ (18,917) | | Net Loss Per Share (Basic and diluted) | $ (8.59) | $ (23.62) | - Subsequent to year-end, on **February 20, 2024**, the company raised **$2,605,000** through a private placement of Series A Preferred Stock and warrants, also converting outstanding convertible notes[499](index=499&type=chunk)[500](index=500&type=chunk) [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](index=91&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20with%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) The company reports no changes in or disagreements with its accountants on accounting and financial disclosure - None [Controls and Procedures](index=91&type=section&id=Item%209A%20Controls%20and%20Procedures) Management concluded that disclosure controls were not effective as of **December 31, 2023**, due to a material weakness in internal control over financial reporting from a lack of segregation of duties - The CEO and CFO concluded that as of **December 31, 2023**, the company's disclosure controls and procedures were not effective at a reasonable assurance level[506](index=506&type=chunk) - A **material weakness** was identified in internal control over financial reporting due to a lack of segregation of duties, attributed to the company's limited size and resources[507](index=507&type=chunk)[508](index=508&type=chunk) - The company plans to remediate the material weakness by increasing the capacity of its qualified financial personnel[509](index=509&type=chunk) [Other Information](index=92&type=section&id=Item%209B%20Other%20Information) The company reports no other information - None [Disclosure Regarding Foreign Jurisdictions that Prevent Inspections](index=92&type=section&id=Item%209C%20Disclosure%20Regarding%20Foreign%20Jurisdictions%20that%20Prevent%20Inspections) This item is not applicable to the company - None Part III [Directors, Executive Officers and Corporate Governance](index=93&type=section&id=Item%2010%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) The company's Board of Directors consists of **seven members**, including **four independent directors**, and has established three standing committees, along with adopting a clawback policy - The Board of Directors consists of **seven members**, with **four** determined to be independent[531](index=531&type=chunk)[533](index=533&type=chunk) - The Board has established an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee[534](index=534&type=chunk) - On **November 28, 2023**, the Board adopted an executive compensation recoupment (clawback) policy consistent with Exchange Act Rule 10D-1[540](index=540&type=chunk) [Executive Compensation](index=99&type=section&id=Item%2011%20Executive%20Compensation) In fiscal year 2023, named executive officers received total compensation ranging from **$350,225** to **$487,600**, with independent directors receiving **$232,500** in cash compensation | Name and Principal Position | Year | Salary ($) | Bonus ($) | Option/RSU Awards($) | Total ($) | | :--- | :--- | :--- | :--- | :--- | :--- | | Steven M. Foster, CEO | 2023 | 400,000 | 87,600 | — | 487,600 | | | 2022 | 300,000 | 70,000 | 1,926,634 | 2,296,634 | | Steven Van Dick, CFO | 2023 | 325,000 | 60,225 | — | 385,225 | | | 2022 | 275,000 | 148,125 | 808,998 | 1,232,123 | | Richard Ginn, CTO | 2023 | 290,000 | 60,225 | — | 350,225 | | | 2022 | 275,000 | 148,125 | 3,995,603 | 4,418,728 | - Employment agreements for executive officers include severance equal to **one year's base salary** and **12 months** of health care coverage upon termination without cause or for good reason[553](index=553&type=chunk)[557](index=557&type=chunk)[561](index=561&type=chunk) - Independent directors received **$232,500** in total cash compensation for board and committee service in 2023, with no equity compensation issued[573](index=573&type=chunk)[574](index=574&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=104&type=section&id=Item%2012%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) As of **March 29, 2024**, all directors and executive officers as a group beneficially owned **5.6%** of common stock, with Zuhlke Ventures AG holding **9.4%** and other significant Series A Preferred Stock holders - All officers and directors as a group beneficially own **209,133 shares**, representing **5.6%** of outstanding common stock as of **March 29, 2024**[586](index=586&type=chunk) - Zuhlke Ventures AG is a **5% or greater stockholder**, beneficially owning **244,773 shares** of common stock, or **9.4%**[586](index=586&type=chunk) - The Beckham-Shufeldt Family Trust and Ascent Special Ventures LLC are significant holders of Series A Preferred Stock, with beneficial ownership of **25.7%** and **26.4%** respectively[586](index=586&type=chunk) [Certain Relationships and Related Party Transactions, and Director Independence](index=106&type=section&id=Item%2013%20Certain%20Relationships%20and%20Related%20Party%20Transactions%2C%20and%20Director%20Independence) The company has a consulting agreement with Richard Ferrari, its Executive Chairman, dated May 7, 2021, for his services - The company has a consulting agreement with Richard Ferrari, its Executive Chairman, dated **May 7, 2021**[588](index=588&type=chunk) [Principal Accountant Fees and Services](index=106&type=section&id=Item%2014%20Principal%20Accountant%20Fees%20and%20Services) Haskell & White LLP was engaged as the independent auditor for 2023 with **$158,500** in fees, while Armanino LLP served as auditor for 2022 and prior, with **$234,083** in 2023 and **$410,893** in 2022 | Fees Paid to H&W (2023) | Amount | | :--- | :--- | | Audit fees | $158,500 | | Total fees | $158,500 | | Fees Paid to Armanino | 2023 | 2022 | | :--- | :--- | :--- | | Audit fees | $179,102 | $338,253 | | Audit-related fees | $54,981 | $72,640 | | Total fees | $234,083 | $410,893 | Part IV [Exhibits, Financial Statement Schedules](index=107&type=section&id=Item%2015%20Exhibit%20and%20Financial%20Statement%20Schedules) This section provides an index of all exhibits filed as part of the Annual Report, including consolidated financial statements and various corporate documents - This section provides an index of all exhibits filed with the 10-K, including corporate governance documents, material agreements, and certifications[596](index=596&type=chunk)

Financial Performance - Fourth quarter 2023 revenue increased 192% year-over-year to $808,000, while full year 2023 revenue rose 324% to $2.9 million[5] - Gross profit for the full year 2023 was $1.2 million, a significant improvement from a gross loss of $641,000 in 2022[5] - Operating losses for the fourth quarter of 2023 totaled $3.1 million, a decrease from $7.9 million in the same period of 2022[10] - Net loss for the year ended December 31, 2023, was $15.6 million, compared to a net loss of $18.9 million in the prior year[11] - As of December 31, 2023, cash and cash equivalents totaled $2.4 million, an increase from $2.1 million at the end of 2022[13] Surgical Procedures and Training - Surgical procedures utilizing the Catamaran System increased by 312% year-over-year for the full year 2023, with a 179% increase in the fourth quarter[5] - The company hosted 133 physicians in Catamaran-focused training sessions throughout 2023, including a webinar series in Q4 attended by over sixty healthcare providers[4] Future Plans - The company plans to expand educational activities and refine its product offerings in 2024 based on feedback from physician customers[6] - Tenon issued approximately $3.85 million of Series A Preferred Stock, raising approximately $2.6 million in gross proceeds and retiring $1.25 million in secured debt[5] Gross Margin - Gross margin reached 69% in the fourth quarter of 2023, up from 57% in Q3 2023[5]

Financial Data and Key Metrics Changes - For the full year of 2023, revenue grew 324% to $2.9 million, and gross profit increased to $1.2 million compared to a gross loss for the full year of 2022 [6][9][21] - Operating losses totaled $3.1 million in the fourth quarter compared to a loss of $7.9 million in the fourth quarter of 2022, and for the year ended December 31, 2023, operating losses totaled $15.7 million compared to $18.7 million in the prior year [10][38] - Gross margin improved to 69% in the fourth quarter, up from 57% in the third quarter [17] Business Line Data and Key Metrics Changes - The Catamaran System experienced a 312% increase in the number of surgical procedures from the prior year, driving strong revenue growth with a 192% increase year-over-year [33][37] - The company trained 28 physicians in the fourth quarter and 133 over the entire year [25] Market Data and Key Metrics Changes - The company ended the fourth quarter with solid momentum in revenue and a third consecutive quarter of positive gross margin [23] - Cash and cash equivalents totaled $2.4 million as of December 31, 2023, down from $8.6 million as of December 31, 2022 [22] Company Strategy and Development Direction - The company focuses on building market share and enhancing commercialization efforts for the Catamaran System [16] - There is a commitment to validating patient outcomes and expanding the application of the product offering to address SI revision surgery and adjunct to multilevel fusion [40] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for continued growth in commercialization, supported by an expanding sales and marketing infrastructure [23] - The company expects to incur additional losses in the future but remains focused on achieving long-term value for shareholders [38] Other Important Information - The company successfully passed a full Quality System Inspection Technique (QSIT) Level 2 inspection conducted by the FDA, validating its quality system and operational procedures [19] Q&A Session Summary Question: How many surgeons did you train during the quarter? - The company trained 28 physicians over the quarter and 133 over the entire year [25] Question: What is the final enrollment number for the post-approval study? - The study was approved for 50 patients, with an expected final enrollment between 40 and 50 [26] Question: Do you have a target for physician training per quarter in 2024? - The company aims to train approximately 25 to 30 well-targeted physicians each quarter [45] Question: What trends are you seeing in the utilization of the Catamaran System? - The number of procedures is still growing, with physicians increasingly incorporating SI into their practice [46] Question: What has been the reception of the new instrumentation kit? - The reaction to the new JIB technology has been outstanding, improving visualization during procedures [48]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ to __________ COMMISSION FILE NUMBER 001-41364 TENON MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisd ...

As filed with the Securities and Exchange Commission on September 11, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tenon Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 3841 45-5574718 (I.R.S. Employer Identification No.) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) 104 Cooper Court Los ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) COMMISSION FILE NUMBER 001-41364 TENON MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 45-5574718 (State or other jurisdiction of incorporation or organization) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...